New Data: GLP-1 Users Move Less, Lose Muscle; Peloton's Healthspan Strategy and AI-Powered Strength Offer Solution

For four years Peloton has been the most reliable punchline in business writing: the $50bn pandemic bubble, the bikes on Facebook Marketplace, the Christmas ad, the treadmill recall. It was the cautionary tale every strategy deck needed. Underneath the joke, something else was happening. On 6 August 2026 Peloton reported fiscal 2026 revenue of $2.446bn and net income of $63.2m — the first full year of profitability in the company's history — with adjusted EBITDA of $468.2m, free cash flow of $377.6m and subscription gross margin of 73.6%. "Fiscal 2026 was a defining milestone," said CEO Peter Stern, who took the job in January 2025. The company that was supposed to be a zombie now throws off cash. The strategic move underneath the numbers is the part nobody has written about. In his first annual letter in January 2026, Stern moved the company's stated purpose off weight and onto healthspan — helping people live "fit, strong, long and happy" — and called it "the defining opportunity of Peloton's next era." He named three pillars: strength alongside cardio, commercial fitness through Precor, and AI personalisation. And in the same letter he named the reason for the strength pillar out loud: people on GLP-1 medications who need to keep their muscle. He was early. Six months later the evidence landed. Dr Sajana Maharjan's team at HSHS St. John's Hospital linked NIH All of Us health records to Fitbit data for 753 adults with obesity who started a GLP-1, and found activity going backwards, with the steepest declines among men and among people reporting joint or muscle pain. Her conclusion was blunt: "Exercise cannot be optional for people taking these medications." Access, meanwhile, went vertical. The FDA approved orforglipron — a pill, branded Foundayo, no injection and no refrigeration — on 1 April 2026, at $149 a month self-pay and as little as $25 with a savings card. The Medicare GLP-1 Bridge opened on 1 July at a $50 monthly copay, running to the end of 2027. Gallup's June poll put current use at 11% of US adults, nearly quadruple 2024, with US obesity down to 36.4% from a 39.9% peak. Which leaves a gap the size of a market. Tens of millions of people are losing weight chemically, moving less while they do it, and losing lean mass in the process — and the industry's response so far is a leaflet. Peloton has two million members doing strength programming in any given quarter, an instructor bench people are genuinely attached to, and since October 2025 a computer-vision system, Peloton IQ, that counts reps, gives form feedback and builds adaptive plans from a 50,000-class library. More than half of monthly active users engage with its insights, and Stern told analysts in August it is "the number one feature of interest from our potential customers." The company has told Bloomberg, in March, that its campaigns would target GLP-1 users. It has said almost nothing publicly since. There is no Peloton GLP-1 programme, no partnership with a telehealth prescriber, no named clinical advisory board. The strongest position in connected fitness is sitting unclaimed, held by a brand whose public narrative is still a joke from 2022. It is not a redemption story and Peloton should not pitch it as one. Connected Fitness subscriptions fell 8.8% to 2.553 million last year, churn ticked up 37 basis points after the first price rise in seven years, hardware revenue fell 14%, guidance for fiscal 2027 is lower again, and in November 2025 the company recalled 833,000 Bike+ seat posts after two injuries. This is a smaller, harder, better-run company than the one that IPO'd. That is precisely what makes the strength story credible rather than promotional: it is being told by a business that has already stopped pretending.